ClinicalTrials.gg
Not yet recruitingNCT07937774TCMA-OCDUpdated Nov 16, 2026

Traditional Chinese Medicine Augmentation Therapy for Obsessive-Compulsive Disorder

A Phase 1/2 interventional study of Chaixia Dingzhi Powder and Placebo Group in Obsessive-Compulsive Disorder, OCD and Traditional Chinese Medicine (TCM), sponsored by Shanghai Mental Health Center. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Shanghai Mental Health Center · Phase 1/2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center — 15 open to participants now, 15 under way, none of them phase 3. Obsessive-Compulsive Disorder · Shanghai Mental Health Center.

Planned enrollment
9th of 24
76 · median 60
Started
2026
with 3 others
Phase 1/2
Only one
of the 27
Primary completion
2027-07
later than 9 of 14 live
Registered
27th of 27
by date

Among the 27 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, this one is the 9th largest by planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 9 of the 14 other live ones, and was the 27th registered.

Obsessive-Compulsive Disorder

636 studies on the registry are indexed under Obsessive-Compulsive Disorder; 165 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

15 of the 27 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 119 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 81 (68%) stop at 75 or younger; 28 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by recurrent intrusive obsessive thoughts, urges, and ritualized compulsive behaviors. OCD often follows a chronic and protracted course with a high risk of relapse and is frequently accompanied by comorbid anxiety, depression, and other negative emotional symptoms, resulting in substantial impairment in occupational functioning, interpersonal relationships, and family and social functioning.Integrative treatment combining traditional Chinese medicine (TCM) and Western medicine may help address several limitations of conventional monotherapy, including suboptimal treatment response rates, medication-related adverse effects, the limited diversity of available therapeutic approaches, and insufficiently individualized treatment strategies, thereby offering potential clinical benefits.Chaixia Dingzhi Powder, the investigational Chinese herbal formula used in this study, was developed based on the formulation principles of two classical TCM prescriptions, Xiaoyao San (Free and Easy Wanderer Powder), documented in the Taiping Huimin Heji Jufang (Formulary of the Pharmacy Service for Benefiting the People in the Taiping Era), and Banxia Houpo Tang (Pinellia and Magnolia Bark Decoction), recorded in the Jingui Yaolue (Essentials from the Golden Cabinet). The formula was further modified according to the TCM pathophysiological characteristics of the target population, particularly liver qi stagnation with spleen deficiency, impaired qi movement, and the interaction of phlegm and qi stagnation.Therefore, this study aims to further investigate the efficacy and safety of Chaixia Dingzhi Powder as an adjunctive traditional Chinese medicine (TCM) treatment in patients with obsessive-compulsive disorder (OCD) who have demonstrated nonresponse to initial SSRI treatment, while maintaining their existing SSRI therapy at an adequate therapeutic dose or the maximum tolerated dose.

03

Conditions studied

  • Obsessive-Compulsive Disorder
  • OCD
  • Traditional Chinese Medicine (TCM)
  • Therapy
  • Non
  • Nonrespond
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1)Aged 16-65 years; 2)Meet the diagnostic criteria for obsessive-compulsive disorder (OCD) according to the , Fifth Edition (DSM-5); 3)Have received continuous SSRI monotherapy at the maximum recommended dose or maximum tolerated dose for at least 8 consecutive weeks; 4)Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score >12 or a Clinical Global Impression-Severity (CGI-S) score ≥3; 5)Meet the traditional Chinese medicine (TCM) syndrome differentiation criteria for liver qi stagnation and spleen deficiency.

Exclusion criteria

Exclusion Criteria:

1)Meet the diagnostic criteria for any psychiatric disorder other than obsessive-compulsive disorder (OCD), with the exception of obsessive-compulsive personality disorder (OCPD); 2)Meet the criteria for treatment-resistant obsessive-compulsive disorder (TR-OCD) as defined in the Chinese Guidelines for the Prevention and Treatment of Obsessive-Compulsive Disorder; 3) Meet the traditional Chinese medicine (TCM) syndrome differentiation criteria for any syndrome other than liver qi stagnation and spleen deficiency; 4)Women who are pregnant, planning to become pregnant in the near future, or breastfeeding; 5)Have a history of substance abuse within the past 12 months; 6) Have a history of severe drug allergies; 7)Have any other condition that, in the investigator's judgment, makes them unsuitable for participation in the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Chai-Xia Ding-Zhi Powder Group

    Drug: Chaixia Dingzhi Powder

  • Placebo comparator
    Control Group

    Placebo Group

    Drug: Placebo Group

Interventions

  • DrugChaixia Dingzhi Powder

    Participants will receive Chai-Xia Ding-Zhi Powder as an adjunctive treatment for 8 weeks while continuing SSRIs at their original dosage.

  • DrugPlacebo Group

    Participants will receive Chai-Xia Ding-Zhi Powder placebo as an adjunctive treatment for 8 weeks while continuing SSRIs at their original dosage.

06

What researchers measure

Primary outcomes

  1. Y-BOCS Score

    Time frame: 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937774
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Lanying LIU
Contact
balindaliu@126.com
13516816012

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion